FundedIQ
Biotechnology

Elegen: Funding, Investors & Team (Sep 2026)

Elegen is a biotechnology company founded in 2017 by Dr. Matthew Hill, focused on developing microfluidic technology for use in DNA synthesizers to drive biomedical advancements.

www.elegenbio.com LinkedIn San Carlos, United States 51-100 employees
Total raised
$35.0M
Rounds
1
Latest
Series B
May 2024

Elegen has raised $35.0M across 1 funding round on record, the most recent a Series B of $35.0M announced in May 2024.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Elegen Company Profile and Key Stats

Total funding raised
$35.0M
across 1 round on record
Funding rounds on record
1
Latest funding round
Series B
$35.0M in May 2024
Employees
51-100
reported band
Headquarters
San Carlos, United States

Latest funding round on record: May 2024.

Elegen Funding Rounds

Date
Round
Amount
Series B
$35.0M

Elegen Founders and Leadership Team

Name
Role
Contact
Matthew Hill
Founder
Locked

Contact details for the Elegen team: 1 of 1 has an email address on file.

Start 14-day free trial →

Elegen Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,182
$8.0M
29,795
$7.5M
4,307
$30M

Elegen's latest round of $35.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Elegen in Biotechnology and San Carlos

Companies Similar to Elegen

Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…

Series B $65.5M

Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…

Seed $7.0M

ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…

Series C $10.0M

EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…

Series A $35.0M

Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…

Convertible Note $3.5M

Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…

Convertible Note $6.8M

XiltriX North America is an information technology company that specializes in monitoring, predictive…

Undisclosed round $3.0M

Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…

Seed $3.1M

Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…

Series D $66.0M

Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…

Series B $92.7M

Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…

Series C $110M

InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…

Series B $77.0M

Elegen Funding FAQs

What does Elegen do?

Elegen is a biotechnology company founded in 2017 by Dr. Matthew Hill, focused on developing microfluidic technology for use in DNA synthesizers to drive biomedical advancements.

How much funding has Elegen raised?

Elegen has raised $35.0M across 1 round on record. The most recent is a Series B of $35.0M announced in May 2024.

When did Elegen last raise funding?

Elegen's most recent funding round on record is a Series B of $35.0M, announced in May 2024.

Who founded Elegen?

FundedIQ lists Matthew Hill (Founder) at Elegen.

Where is Elegen headquartered?

Elegen is based in San Carlos, California, United States.

How many employees does Elegen have?

Elegen is in the 51-100 employee band.

How does Elegen's funding compare to other Biotechnology startups?

Elegen's latest round of $35.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.

About FundedIQ's Elegen Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Elegen is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.